Heart failure drug vericiguat under Real-World review in india
NCT ID NCT06632483
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study looks back at medical records of over 600 Indian adults with chronic heart failure who were prescribed vericiguat between 2022 and 2023. Researchers want to see how the drug is used in routine care, how it affects heart function and hospital stays, and whether side effects like low blood pressure occur. No new tests or visits are needed—only existing data is collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Many locations
Multiple Locations, India
Conditions
Explore the condition pages connected to this study.